ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

By S. Wedge, D. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J. Jackson, S. Boffey, P. J. Valentine, J. Curwen, H. Musgrove and 9 more. Cancer Research, 2002

888 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/21d227845f372f61f75e2a59dd611151b6bff07e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Fagin
2. Fortunato Ciardiello
3. G. Tortora
4. Sreenath V. Sharma
5. S. Wedge
6. F. Carlomagno
7. J. Settleman
8. S. Wells

Citations in the corpus

• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. (2005, methodology): “was done (29), with growth plate areas from both the femur and tibia in each joint being combined for an analysis of the effect of compound”
• Epidermal growth factor receptor mutations in lung cancer (2007, background): “Consistent with this concept, the dual EGFR and VEGFR inhibitor ZD647”
• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002, background): “ZD6474 is currently under Phase I evaluation in cancer patients ( 15 ).”
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (2012, background): “Vandetanib is a once-daily oral agent that selectively targets RET, VEGFR, and EGFR signaling.(12,16) We report the results of an international, randomized, placebo-controlled, double-blind, phase III study (ZETA) to evaluate vandetanib 300 mg/d in patients with locally advanced or metastatic MTC.”